SCHEDULE: FMR LLC and Abigail Johnson Report 5.3% Stake in Cartesian Therapeutics
Beneficial Ownership Report
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have reported a beneficial ownership of 5.3% in Cartesian Therapeutics Inc. as of December 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 1,366,989 shares of Cartesian Therapeutics Inc. common stock.
- This ownership represents 5.3% of the total outstanding common stock of Cartesian Therapeutics Inc.
- FMR LLC holds sole voting power over 1,366,854 shares and sole dispositive power over 1,366,989 shares.
- Abigail P. Johnson holds sole dispositive power over 1,366,989 shares, with no sole or shared voting power directly attributed to her in this filing.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- FMR LLC is classified as a parent holding company, and Abigail P. Johnson is classified as an individual reporting person.
- Fidelity Management & Research Company LLC (an investment adviser) and Fidelity Management Trust Company (a bank) are identified as relevant entities within FMR LLC's structure that beneficially own shares.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development. A significant stake by a reputable institutional investor like FMR LLC, held in the ordinary course of business, can be interpreted as a vote of confidence in the company's long-term value, without indicating any immediate operational changes or activist intentions.
Positives
- A significant stake by a major institutional investor like FMR LLC can signal confidence in Cartesian Therapeutics Inc.'s long-term prospects.
- The acquisition of shares in the ordinary course of business suggests a strategic investment rather than an activist position, potentially indicating stability.
Negatives
- No explicit negative information is contained within this Schedule 13G filing, which primarily reports beneficial ownership.
Risks
- The filing does not detail specific risks related to Cartesian Therapeutics Inc.'s operations or financial health, as it is an ownership disclosure.
Industry Context
StockSavvy.ai notes that the reporting of a significant stake by FMR LLC, a prominent asset management firm, in a biotechnology company like Cartesian Therapeutics Inc. is a common occurrence as institutional investors build positions in promising sectors. This type of filing provides transparency into major ownership structures, which is crucial for market participants in the biotech industry, often characterized by high growth potential and significant capital requirements.
Related Party Transactions
- Abigail P. Johnson, a reporting person, is a Director, Chairman, and CEO of FMR LLC, the other reporting person. Members of the Johnson family, including Abigail P. Johnson, are predominant owners of FMR LLC's voting common shares and have a voting agreement, potentially forming a controlling group with respect to FMR LLC.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holder may increase investor confidence and potentially attract further institutional interest.
- Management: The presence of a major institutional investor typically encourages strong corporate governance and strategic alignment.
Next Steps
- FMR LLC and Abigail P. Johnson will be required to file subsequent amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., by more than 1% of the class) or if their intent regarding the investment changes.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its direct and indirect subsidiaries. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where its Power of Attorney (accession number: -23-000003) was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Abigail P. Johnson's Power of Attorney (accession number: -23-000038) was incorporated by reference. |
| 2025-12-31 | Date of event which requires filing of this statement, representing the beneficial ownership position. |
| 2026-02-04 | Date the Schedule 13G (Amendment No. 3) was signed and filed. |
Recommendation
holdThe filing indicates a significant institutional stake by FMR LLC, which is generally a positive signal of confidence. However, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It suggests a stable, long-term institutional interest, making 'hold' an appropriate recommendation for existing investors, while new investors might consider it a positive factor for further due diligence.
Keywords
Cartesian Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.